Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 133

Sort by

Sort Order Select

Journal Articles

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Swaminathan P Iyer, LaQuisa Hill, Steven Horwitz, Salvia Jain, Christina Poh, Julie M. Vose, Malcolm K. Brenner, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Bexon

Blood (2024) 144 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2024-201523

Published: 2024

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

Combining Apoptotic Resistance and Cytokine Signaling to Improve Persistence and Anti-Tumor Activity of CAR Vδ2 T Cells In Vivo

Leonard Leong, Mansi Narula, Helen Elisabeth Heslop, Malcolm K. Brenner, Maksim Mamonkin, Norihiro Watanabe

Blood (2023) 142 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2023-187658

Published: 2023

Journal Articles

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Feiyan Mo, Norihiro Watanabe, Kayleigh I. Omdahl, Phillip M. Burkhardt, Xiaoyun Ding, Eiko Hayase, Angela Panoskaltsis-Mortari, Robert R. Jenq, Helen E. Heslop, Leslie S. Kean, Malcolm K. Brenner, Victor Tkachev, Maksim Mamonkin

Blood (2023) 141 (10): 1194–1208.

https://doi.org/10.1182/blood.2022016052

Published: 2023

Includes: Supplemental data

Journal Articles

LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia

Lauren Scherer, Candise Tat, Tim Sauer, Haruko Tashiro, Swati Naik, Mireya Paulina Velasquez, Stephen Gottschalk, Cliona M. Rooney, Malcolm K. Brenner, Bilal Omer

Blood (2022) 140 (Supplement 1): 7396–7397.

https://doi.org/10.1182/blood-2022-170503

Published: 2022

Journal Articles

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood (2022) 140 (Supplement 1): 412–414.

https://doi.org/10.1182/blood-2022-160244

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Rayne H. Rouce, LaQuisa C. Hill, Tyler S. Smith, Lina Yang, Blakely Boriskie, Madhuwanti Srinivasan, Huimin Zhang, Silvana Perconti, Birju Mehta, Olga Dakhova, Bambi J. Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin

Blood (2021) 138 (Supplement 1): 654.

https://doi.org/10.1182/blood-2021-154142

Published: 2021

Journal Articles

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Blood (2021) 137 (19): 2585–2597.

https://doi.org/10.1182/blood.2020009471

Published: 2021

Includes: Supplemental data

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141491

Published: 2020

Journal Articles

Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia

Pinar Ataca Atilla, MD, Mary K McKenna, PhD, Norihiro Watanabe, PhD, Maksim Mamonkin, PhD, Malcolm K. Brenner, MD PhD, Erden Atilla, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141540

Published: 2020

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

Journal Articles

Single Cell RNA Sequencing Identifies Transcriptional Programs That Enhance Anti-Tumor Function of Transgenic CD4+ T Cells Redirected with TCR and CD8αβ

Jan A Rath, MS, Gagan Bajwa, PhD, Benoit Carreres, MS, Isabelle Gruber, MS, Elisabeth Hoyer, BS, Meng-Fen Wu, MS, Yi-Ru Yu, PhD, Ping-Chih Ho, PhD, Malcolm K. Brenner, MD PhD, David Gfeller, PhD, Caroline Arber, MD

Blood (2019) 134 (Supplement_1): 250.

https://doi.org/10.1182/blood-2019-124714

Published: 2019

Journal Articles

Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia

Pinar Ataca Atilla, MD, Haruko Tashiro, MD PhD, Mary Kathryn McKenna, PhD, Madhuwanti Srinivasan, Brian Wesley Simons, Alexandra McLean Stevens, MD PhD, Michele Redell, MD PhD, Maksim Mamonkin, PhD, Malcolm K. Brenner, MD PhD, Erden Atilla, MD

Blood (2019) 134 (Supplement_1): 3912.

https://doi.org/10.1182/blood-2019-127953

Published: 2019

Journal Articles

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Lauren P. McLaughlin, Rayne Rouce, Stephen Gottschalk, Vicky Torrano, George Carrum, Meng-Fen Wu, Fahmida Hoq, Bambi Grilley, Andrea M. Marcogliese, Patrick J. Hanley, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard

Blood (2018) 132 (22): 2351–2361.

https://doi.org/10.1182/blood-2018-07-863654

Published: 2018

Journal Articles

Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

Premal Lulla, MBBS, Ifigeneia Tzannou, MD, George Carrum, MD, Carlos A. Ramos, MD, Rammurti Kamble, MD, Mrinalini Bilgi, Shivani Mukhi, Betty Chung, DO,MPH,MA, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, PhD, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2018-99-113118

Published: 2018

Journal Articles

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Carlos A. Ramos, MD, Mrinalini Bilgi, Claudia P. Gerken, Olga Dakhova, Zhuyong Mei, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Cliona M. Rooney, PhD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Helen E. Heslop, MDDSc, Malcolm K. Brenner, MD PhD

Blood (2018) 132 (Supplement 1): 680.

https://doi.org/10.1182/blood-2018-99-111202

Published: 2018

Journal Articles

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

George Carrum, MD, Premal Lulla, MBBS, Ifigeneia Tzannou, MD, Ayumi Watanabe, Manik Kuvalekar, Mrinalini Bilgi, Rammurti Kamble, MD, Carlos A. Ramos, MD, Rayne Rouce, MD, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Cliona M. Rooney, PhD, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1685.

https://doi.org/10.1182/blood-2018-99-113140

Published: 2018

Journal Articles

c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals

Christopher D. Nishimura, Daniel A. Brenner, Malini Mukherjee, Rachel A. Hirsch, Leah Ott, Meng-Fen Wu, Hao Liu, Olga Dakhova, Jordan S. Orange, Malcolm K. Brenner, Charles Y. Lin, Caroline Arber

Blood (2017) 130 (25): 2739–2749.

https://doi.org/10.1182/blood-2017-02-769463

Published: 2017

Includes: Supplemental data

NARROW

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Combining Apoptotic Resistance and Cytokine Signaling to Improve Persistence and Anti-Tumor Activity of CAR Vδ2 T Cells In Vivo

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

Single Cell RNA Sequencing Identifies Transcriptional Programs That Enhance Anti-Tumor Function of Transgenic CD4+ T Cells Redirected with TCR and CD8αβ

Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only